| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Boyer Center for Molecular Medicine, Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06536 [A. G., N. R. W., D. C. A.]; University of Oklahoma Health Sciences Center, Biomedical Research Center, Oklahoma City, Oklahoma 73104 [M. J. K., G. J. G.]; Vita-Salute University School of Medicine, San Raffaele Scientific Institute, Milano 20132, Italy [S. T., P. C. M.]; and Center for Oncology and Cell Biology, North Shore-Long Island Jewish Research Institute, Manhasset, New York 11030 [M. S.]
Survivin is a member of the inhibitor of apoptosis (IAP) gene family, which has been implicatedin both preservation of cell viability and regulation of mitosis in cancercells. Here, we show that HeLa cells microinjected with a polyclonal antibody to survivin exhibited delayed progression in prometaphase (31.5 ± 6.9 min) and metaphase (126.8 ± 73.8 min), as compared with control injected cells (prometaphase, 21.5 ± 3.3 min; metaphase, 18.9 ± 4.5 min; P < 0.01). Cells injected with the antibody to survivin displayed short mitotic spindles severely depleted of microtubules and occasionally underwent apoptosis without exiting the mitotic block or thereafter. Forced expression of survivin in HeLa cells profoundly influenced microtubule dynamics with reduction of pole-to-pole distance at metaphase (8.57 ± 0.21 µm versus 10.58 ± 0.19 µm; P < 0.0001) and stabilization of microtubules against nocodazole-induced depolymerization in vivo. These data demonstrate that survivin functions at cell division to control microtubule stability and assembly of a normal mitotic spindle. This pathway may facilitate checkpoint evasion and promote resistance to chemotherapy in cancer.
This article has been cited by other articles:
|
|
 |
|
  R. Hino, H. Uozaki, Y. Inoue, Y. Shintani, T. Ushiku, T. Sakatani, K. Takada, and M. Fukayama Survival Advantage of EBV-Associated Gastric Carcinoma: Survivin Up-regulation by Viral Latent Membrane Protein 2A Cancer Res., March 1, 2008; 68(5): 1427 - 1435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Andersen, I. M. Svane, J. C. Becker, and P. t. Straten The Universal Character of the Tumor-Associated Antigen Survivin Clin. Cancer Res., October 15, 2007; 13(20): 5991 - 5994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nakahara, M. Takeuchi, I. Kinoyama, T. Minematsu, K. Shirasuna, A. Matsuhisa, A. Kita, F. Tominaga, K. Yamanaka, M. Kudoh, et al. YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts Cancer Res., September 1, 2007; 67(17): 8014 - 8021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Leung, Y. Xu, B. Mularski, H. Liu, S. Gurbuxani, and J. D. Crispino Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells J. Exp. Med., July 9, 2007; 204(7): 1603 - 1611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pennati, M. Folini, and N. Zaffaroni Targeting survivin in cancer therapy: fulfilled promises and open questions Carcinogenesis, June 1, 2007; 28(6): 1133 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M.R. Bhat and V. Setaluri Microtubule-Associated Proteins as Targets in Cancer Chemotherapy Clin. Cancer Res., May 15, 2007; 13(10): 2849 - 2854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. P. Blanc-Brude, E. Teissier, Y. Castier, G. Leseche, A.-P. Bijnens, M. Daemen, B. Staels, Z. Mallat, and A. Tedgui IAP Survivin Regulates Atherosclerotic Macrophage Survival Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 901 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rosa, P. Canovas, A. Islam, D. C. Altieri, and S. J. Doxsey Survivin Modulates Microtubule Dynamics and Nucleation throughout the Cell Cycle Mol. Biol. Cell, March 1, 2006; 17(3): 1483 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Xia, J. Bisi, J. Strum, L. Liu, K. Carrick, K. M. Graham, A. L. Treece, M. A. Hardwicke, M. Dush, Q. Liao, et al. Regulation of Survivin by ErbB2 Signaling: Therapeutic Implications for ErbB2-Overexpressing Breast Cancers Cancer Res., February 1, 2006; 66(3): 1640 - 1647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bozko, M. Sabisz, A. K. Larsen, and A. Skladanowski Cross-talk between DNA damage and cell survival checkpoints during G2 and mitosis: pharmacologic implications Mol. Cancer Ther., December 1, 2005; 4(12): 2016 - 2025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pennati, A. J. Campbell, M. Curto, M. Binda, Y. Cheng, L.-Z. Wang, N. Curtin, B. T. Golding, R. J. Griffin, I. R. Hardcastle, et al. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation Mol. Cancer Ther., September 1, 2005; 4(9): 1328 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Soukoulis, S. Reddy, R. D. Pooley, Y. Feng, C. A. Walsh, and D. M. Bader Cytoplasmic LEK1 is a regulator of microtubule function through its interaction with the LIS1 pathway PNAS, June 14, 2005; 102(24): 8549 - 8554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Yang, A. Welm, and J. M. Bishop Cell division and cell survival in the absence of survivin PNAS, October 19, 2004; 101(42): 15100 - 15105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Schimmer Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice Cancer Res., October 15, 2004; 64(20): 7183 - 7190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Beardmore, L. J. Ahonen, G. J. Gorbsky, and M. J. Kallio Survivin dynamics increases at centromeres during G2/M phase transition and is regulated by microtubule-attachment and Aurora B kinase activity J. Cell Sci., August 15, 2004; 117(18): 4033 - 4042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Dohi, K. Okada, F. Xia, C. E. Wilford, T. Samuel, K. Welsh, H. Marusawa, H. Zou, R. Armstrong, S.-i. Matsuzawa, et al. An IAP-IAP Complex Inhibits Apoptosis J. Biol. Chem., August 13, 2004; 279(33): 34087 - 34090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Okada, C. Bakal, A. Shahinian, A. Elia, A. Wakeham, W.-K. Suh, G. S. Duncan, M. Ciofani, R. Rottapel, J. C. Zuniga-Pflucker, et al. Survivin Loss in Thymocytes Triggers p53-mediated Growth Arrest and p53-independent Cell Death J. Exp. Med., February 2, 2004; 199(3): 399 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Martinez, B. Bellosillo, F. Bosch, A. Ferrer, S. Marce, N. Villamor, G. Ott, E. Montserrat, E. Campo, and D. Colomer Nuclear Survivin Expression in Mantle Cell Lymphoma Is Associated with Cell Proliferation and Survival Am. J. Pathol., February 1, 2004; 164(2): 501 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Beltrami, J. Plescia, J. C. Wilkinson, C. S. Duckett, and D. C. Altieri Acute Ablation of Survivin Uncovers p53-dependent Mitotic Checkpoint Functions and Control of Mitochondrial Apoptosis J. Biol. Chem., January 16, 2004; 279(3): 2077 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fukuda, C. R. Mantel, and L. M. Pelus Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways Blood, January 1, 2004; 103(1): 120 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Tu, X. H. Jiang, M. C. M. Lin, J. T. Cui, Y. Yang, C. T. Lum, B. Zou, Y. B. Zhu, S. H. Jiang, W. M. Wong, et al. Suppression of Survivin Expression Inhibits in Vivo Tumorigenicity and Angiogenesis in Gastric Cancer Cancer Res., November 15, 2003; 63(22): 7724 - 7732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lohr, C. Moritz, A. Contente, and M. Dobbelstein p21/CDKN1A Mediates Negative Regulation of Transcription by p53 J. Biol. Chem., August 29, 2003; 278(35): 32507 - 32516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Carvalho, M. Carmena, C. Sambade, W. C. Earnshaw, and S. P. Wheatley Survivin is required for stable checkpoint activation in taxol-treated HeLa cells J. Cell Sci., July 15, 2003; 116(14): 2987 - 2998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. P. Blanc-Brude, M. Mesri, N. R. Wall, J. Plescia, T. Dohi, and D. C. Altieri Therapeutic Targeting of the Survivin Pathway in Cancer: Initiation of Mitochondrial Apoptosis and Suppression of Tumor-associated Angiogenesis Clin. Cancer Res., July 1, 2003; 9(7): 2683 - 2692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Loganzo, C. M. Discafani, T. Annable, C. Beyer, S. Musto, M. Hari, X. Tan, C. Hardy, R. Hernandez, M. Baxter, et al. HTI-286, a Synthetic Analogue of the Tripeptide Hemiasterlin, Is a Potent Antimicrotubule Agent that Circumvents P-Glycoprotein-mediated Resistance in Vitro and in Vivo Cancer Res., April 15, 2003; 63(8): 1838 - 1845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kappler, M. Kotzsch, F. Bartel, S. Fussel, C. Lautenschlager, U. Schmidt, P. Wurl, M. Bache, H. Schmidt, H. Taubert, et al. Elevated Expression Level of Survivin Protein in Soft-Tissue Sarcomas Is a Strong Independent Predictor of Survival Clin. Cancer Res., March 1, 2003; 9(3): 1098 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, S. Jin, S. K. Tahir, H. Zhang, X. Liu, A. V. Sarthy, T. P. McGonigal, Z. Liu, S. H. Rosenberg, and S.-C. Ng Survivin Enhances Aurora-B Kinase Activity and Localizes Aurora-B in Human Cells J. Biol. Chem., January 3, 2003; 278(1): 486 - 490. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
